Moleculin Biotech closes $5.9M public offering of stock and Series E warrants

Moleculin Biotech, Inc.

Offered 16,080,000 shares (or pre-funded warrants) and 48,240,000 Series E warrants at $0.37 combined unit, raising ~$5.9M gross.
Series E warrants have $0.37 exercise price, exercisable upon stockholder approval, expire 5 years later; include anti-dilution adjustment floor at $0.12.
CEO Walter V. Klemp and CFO Jonathan P. Foster among insiders buying 1,027,026 shares and 3,081,078 warrants on same terms.
Proceeds to advance Annamycin, other drug portfolios through clinical/preclinical development, sponsor research, and working capital.
Offering closed June 23, 2025; Roth Capital acted as exclusive placement agent, Maxim Group as financial advisor.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.